Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR …
KP Tiev, E Diot, P Clerson, F Dupuis-Siméon… - The Journal of …, 2009 - jrheum.org
Objective. Digital ulcers are the most frequent vascular manifestations of systemic sclerosis (SSc).
Clinical features of patients with prior or current digital ulcers have not been …
Clinical features of patients with prior or current digital ulcers have not been …
[HTML][HTML] Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire
…, S Bekri, A Hagège, F Dupuis-Siméon… - Orphanet Journal of …, 2019 - Springer
Background Fabry disease (FD) is a rare, X-linked, inherited lysosomal disease caused by
absent or reduced α-galactosidase A activity. Due to the heterogeneity of disease …
absent or reduced α-galactosidase A activity. Due to the heterogeneity of disease …
Symptômes et comorbidités associés au diagnostic d'acromégalie chez 472 patients entre 2009 et 2014
…, RP Renoult, A Houchard, F Dupuis-Simeon - Annales d' …, 2015 - Elsevier
Introduction Dans une large cohorte de patients diagnostiqués entre 2009 et 2014, étudier
les symptômes et comorbidités au diagnostic de l’acromégalie. Méthodologie Étude …
les symptômes et comorbidités au diagnostic de l’acromégalie. Méthodologie Étude …
Fabry patients' needs and expectations regarding their treatment in France: Development of a Patients' Need Questionnaire (PNQ Fabry)
…, S Bekri, A Hagège, F Dupuis-Siméon… - Molecular Genetics and …, 2019 - Elsevier
Anderson-Fabry disease (FD) is a rare X-linked inherited lysosomal disease caused by
reduced activity of α-galactosidase A. Due to the heterogeneity of disease presentation and …
reduced activity of α-galactosidase A. Due to the heterogeneity of disease presentation and …
Symptoms and comorbidities at diagnosis of 472 acromegalic patients diagnosed between 2009 and 2014
…, A Houchard, F Dupuis-Simeon - Endocrine …, 2015 - endocrine-abstracts.org
Methods: Observational, cross-sectional, multicentre study conducted in France between
September 2013 and June 2014. Adult patients with acromegaly diagnosed for< 5 years were …
September 2013 and June 2014. Adult patients with acromegaly diagnosed for< 5 years were …
Besoins et attentes des patients atteints de la maladie de Fabry vis-à-vis de leur traitement en France: développement d'un Questionnaire des Attentes des Patients …
…, D Genevaz, S Bekri, A Hagege, F Dupuis… - La Revue de Médecine …, 2019 - Elsevier
Introduction La maladie de Fabry (MF) est une maladie lysosomale génétique, de transmission
liée à l’X, due à une réduction de l’activité de l’enzyme α-galactosidase A. En raison d’…
liée à l’X, due à une réduction de l’activité de l’enzyme α-galactosidase A. En raison d’…
[CITATION][C] Treatment-related benefit and satisfaction in patients with Fabry disease: Insight into patients' expectations and preferences from the SATIS-Fab study
…, B Dussol, S Bekri, F Dupuis-Simeon… - Molecular Genetics and …, 2024 - Elsevier
Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry
C Tolosa-Vilella, ML Morera-Morales… - Seminars in arthritis and …, 2016 - Elsevier
Objective Digital ulcers (DU) are the most common vascular complication of systemic sclerosis
(SSc). We compared the characteristics between patients with prior or current DU with …
(SSc). We compared the characteristics between patients with prior or current DU with …
[PDF][PDF] Le retentissement de l'acromégalie: à propos de 40 cas
N Belmahi, S Elkhadir, H El Ouahabi - Annales d'Endocrinologie, 2017 - congres-sfe.com
Diapositive 1 Page 1 Introduction Introduction L’acromégalie est une maladie rare, liée à une
hypersécrétion d’hormone de croissance par un adénome hypophysaire; très rarement, l’…
hypersécrétion d’hormone de croissance par un adénome hypophysaire; très rarement, l’…
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis
C Zaima, M Kanai, S Ishikawa… - Japanese journal of …, 2011 - academic.oup.com
The safety of chemotherapy for patients with systemic sclerosis is unclear, and there are few
published reports documenting the side effects of chemotherapy in patients with this …
published reports documenting the side effects of chemotherapy in patients with this …